Dasman Diabetes Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Sharq Kuwait (2006)

Organization Overview

First Clinical Trial
2013
NCT01980459
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Dasman Diabetes Institute | Dasman Diabetes Institute. Ministry of Health, Kuwait | Dasmin Diabetes Institute | Nadia Zghoul, PhD, Dept of Clinical Research | Senior diabetes educator in Dasman Diabetes Institute

Active Ingredients

Drugs in Phase 4 Trials (1)

pioglitazone (actos) (1 trial)

Drugs in Phase 2 Trials (2)

epoetin (Epogen) (1 trial)

hmaxi-k (1 trial)

Drugs in Phase 1 Trials (1)

magnesium lactate (1 trial)

Drugs in Other Trials (6)

dapagliflozin (farxiga) (1 trial)

krill oil (1 trial)

liraglutide (victoza) (1 trial)

semaglutide (Ozempic) (1 trial)

vegetable oil (1 trial)

vitamin k2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Erectile Dysfunction (Phase 2)

Inflammation (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 10